Nemes Rush Group LLC Lowers Stake in IQVIA Holdings Inc. (NYSE:IQV)

Nemes Rush Group LLC lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 97.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 540 shares of the medical research company's stock after selling 24,124 shares during the period. Nemes Rush Group LLC's holdings in IQVIA were worth $106,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in IQV. Pine Valley Investments Ltd Liability Co increased its holdings in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after buying an additional 50 shares during the period. Howard Capital Management Inc. increased its stake in shares of IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after acquiring an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after purchasing an additional 56 shares during the period. Cypress Wealth Services LLC boosted its holdings in IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock valued at $244,000 after purchasing an additional 57 shares during the last quarter. Finally, Harbor Investment Advisory LLC grew its position in IQVIA by 4.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock worth $253,000 after purchasing an additional 58 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Barclays lowered their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. Bank of America cut their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Finally, Truist Financial reiterated a "buy" rating and issued a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Trading Down 7.8 %

Shares of IQV traded down $13.06 during midday trading on Friday, reaching $154.63. The company had a trading volume of 2,558,180 shares, compared to its average volume of 1,322,024. IQVIA Holdings Inc. has a 1-year low of $154.35 and a 1-year high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a 50 day simple moving average of $189.67 and a 200-day simple moving average of $203.82. The stock has a market cap of $27.26 billion, a PE ratio of 20.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.